Background
==========

Infiltrating lobular carcinoma (ILC) constitutes approximately 10% of invasive breast cancers, and it is the second common histologic type of breast cancer \[[@B1]\]. In Korea, the incidence of ILC is quite low, and it has been reported as 2-4% of all breast cancers \[[@B2]\]. Recently, the incidence of ILC in the West is relatively increasing, while that of infiltrating ductal carcinoma (IDC) remains constant \[[@B1]\].

It has been reported that ILC has characteristics that are different from IDC \[[@B3]\] such as older age onset, larger tumor size, increased propensity for multifocality and multicentricity, and higher risk of bilateral breast cancer. In terms of histologic features, ILC shows better differentiation, more frequent expression of estrogen receptor (ER)-positive and progesterone receptor (PR), and less vessel invasion. Other characteristics of ILC include lower S-phase fraction and diploid, less HER-2, P53, and epidermal growth factor receptor (EGF-R) expression \[[@B3]\].

While some reported that ILC patients showed better prognosis, others reported poorer prognosis compared with IDC \[[@B4]\]. Limitation of those studies regarding outcomes of ILC is the relatively small sample sizes. The aim of this study was to investigate the clinicopathological features and outcomes of ILC, and compare them with those of infiltrating ductal carcinoma-not otherwise specified (IDC-NOS) in Korean patients.

Methods
=======

We retrospectively reviewed the Severance Hospital Breast Cancer Registry Database of 4,465 breast cancer patients who had been treated at the Department of Surgery, Yonsei University of College of Medicine, Seoul, Korea, between January 1984 and December 2005. Among 4,465 cases, 4,053 were invasive breast cancers: 3,621 IDC-NOS (89.3%), 95 ILC (2.3%) and 337 other types (8.4%). Among 4,053 invasive cancers, 3,621 IDC-NOS and 95 ILC were included in this study.

The patients\' medical records were collected in the Severance Hospital Breast Cancer Registry Database and reviewed to obtain data regarding general characteristics of the patients, histopathology of primary tumors, treatment modalities (surgery, chemotherapy, radiation and hormone therapy), relapse-free survival (RFS) and overall survival (OS). In cases of patients diagnosed with ILC, a specialized pathologist with extensive experience in breast pathology reviewed their pathologic slides, and in cases of patients with IDC, we reviewed these cases through previous pathologic reports. Histological diagnostic features of ILC were loosely dispersed strands of infiltrating tumor cells, often in the form of a single file, throughout the fibrous matrix, lacks of cohesion without formation of tubules or papillae, and small cells with relatively little nuclear pleomorphism \[[@B5]\]. We did not discriminate between classic and variant types. Tumor stages were determined based on the 6th American Joint Committee on Cancer (AJCC) criteria. Histologic types followed the World Health Organization (WHO) classification.

All immunostainings were done with formalin-fixed and paraffin-embedded tissue sections. Briefly, 5 μm-thick sections were obtained with a microtome, deparaffinized and rehydrated. After treatment with 3% hydrogen peroxide solution for 10 minutes to block endogenous peroxidases, the sections were pretreated in 10 mM citrate buffer (pH 6.0) for antigen retrieval in a microwave oven for 20 minutes. After incubation with primary antibodies against ER (clone SP1, 1:100; Thermo Scientific, Fremont, CA, USA), PR (clone PgR 636, 1:50; DAKO, Glostrup, Denmark), and HER-2 (polyclonal, 1:1500; DAKO), immunodetection was performed with biotinylated antimouse immunoglobulin, followed by peroxidase-labeled streptavidin using a labeled streptavidin biotin kit with 3,3\'-diaminobenzidine chromogen as substrate. Slides were counterstained with Harris hematoxylin. Hormone receptor positivity was defined as more than 10 fmol/mg cytosol protein, or as 10% or more nuclear stain by immunohistochemistry (IHC). IHC stain results of HER-2 were scored by counting the number of cells positively stained on the membrane and expressed as a percentage of total tumor cells. HER-2 staining was scored according to the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guideline \[[@B6]\] using the following categories: 0, no immunostaining; 1+, weak incomplete membranous staining in any proportion of tumor cells; 2+, complete membranous staining, either non-uniform or weak in at least 10% of tumor cells; and 3+, uniform intense membranous staining in \>30% of tumor cells.

Associations between categorical variables were assessed using a chi-square test. The RFS time was defined as from the date of the operation to the date of first locoregional or systemic recurrence. Locoregional recurrence included relapses in the chest wall, operation scar, remnant breast, axillary lymph node, supraclavicular lymph node and internal mammary lymph node. Systemic recurrences included metastases in the lung, brain, liver, bone, ovary, kidney and other organs. The OS time was defined as the period between the date of operation and the date of death from any cause. Survival curves were plotted and estimated using the Kaplan-Meier method. Group differences in the survival time were calculated by the log-rank test. The Cox proportional hazard model was used to calculate the hazard ratio (HR) and 95% CI in the analyses of RFS and OS. A p-value less than 0.05 was considered statistically significant. SPSS for Windows (version 15.0, SPSS Inc., Chicago, IL, U.S.A.) was used for all statistical analyses.

Results
=======

The mean follow-up duration was 74 ± 48.19 months in all patients. The mean age at diagnosis was 47.43 ± 8.91 years in ILC patients and 47.69 ± 10.31 years in IDC-NOS patients.

The clinicopathological factors are summarized in Table [1](#T1){ref-type="table"}. There was no difference in the age at diagnosis, tumor size, nodal status and TMN stage. ILC patients showed higher ER expression and less HER-2 expression than IDC-NOS patients (*P*= 0.003 and 0.038, respectively). PR expression was higher in ILC, but, there was no statistical significance. There was a higher incidence of bilateral cancer in the ILC group compared to the IDC-NOS patients (*P*= 0.013).

###### 

Biological characteristics of the patients and tumors by histologic group

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------
                 Histopathology                                                                                                                      
  -------------- ----------------------------------- ------------------------------------ ------------------------- ------- ------------------------ --------------
                 **Infiltrating ductal carcinoma**   **Infiltrating lobular carcinoma**   **Total**                                                  

                                                                                                                                                     

  **Factor**     **Number of patients**\             **%**                                **Number of patients**\   **%**   **Number of patients**   ***P*value**
                 **(n = 3621)**                                                           **(n = 95)**                                               

                                                                                                                                                     

  Age, years                                                                                                                                         0.069

   \>35          3,213                               88.7                                 90                        94.7    3,303                    

   ≤35           406                                 11.3                                 5                         5.3     413                      

                                                                                                                                                     

  T stage                                                                                                                                            0.922

   T1            1,585                               73.8                                 42                        44.2    1,621                    

   T2            1,780                               49.2                                 49                        51.6    1,825                    

   T3            181                                 5                                    3                         3.2     184                      

   T4            72                                  2                                    1                         1.1     73                       

                                                                                                                                                     

  N stage                                                                                                                                            0.56

   N0            1,912                               52.9                                 57                        60      1,969                    

   N1            924                                 25.6                                 22                        23.2    946                      

   N2            459                                 12.7                                 10                        10.5    469                      

   N3            316                                 8.8                                  6                         6.3     322                      

                                                                                                                                                     

  TNM stage                                                                                                                                          0.57

   Stage 1       1,066                               29.5                                 28                        29.5    1,094                    

   Stage 2       1,703                               47.2                                 49                        51.6    1,752                    

   Stage 3       840                                 23.3                                 18                        18.9    858                      

                                                                                                                                                     

  Bilaterality                                                                                                                                       0.013

  Unilateral     3,495                               96.5                                 89                        93.7    3,526                    

  Bilateral      126                                 3.5                                  6                         6.3     132                      

                                                                                                                                                     

  ER receptor                                                                                                                                        0.003

  Negative       1,088                               37.4                                 15                        20.3    1,103                    

  Positive       1,821                               62.6                                 59                        79.7    1,880                    

                                                                                                                                                     

  PR receptor                                                                                                                                        0.23

  Negative       1,221                               42.9                                 25                        35.7    1,246                    

  Positive       1,625                               57.1                                 45                        64.3    1,670                    

                                                                                                                                                     

  HER-2                                                                                                                                              0.038

  Negative       1,373                               70.8                                 46                        83.6    1,419                    

  Positive       567                                 29.2                                 9                         16.4    576                      
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------

ER = estrogen receptor; PR = progesterone receptor; HER-2 = human epidermal growth factor receptor-2.

Treatment modalities including operation methods were not different between the two groups except hormone therapy (Table [2](#T2){ref-type="table"}). As ILC patients showed higher ER expression rates, adjuvant hormone therapy was more frequently given to them (*P*= 0.024)

###### 

Local and systemic adjuvant therapies by histologic type

                 Histopathology                                                                                                                     
  -------------- ----------------------------------- ------------------------------------ ------------------------ ------- ------------------------ --------------
                 **Infiltrating ductal carcinoma**   **Infiltrating lobular carcinoma**   **Total**                                                 
                                                                                                                                                    
                 **Number of patients**              **%**                                **Number of patients**   **%**   **Number of patients**   ***P*value**
                                                                                                                                                    
  Local Tx                                                                                                                                          0.297
  BCS            735                                 20.3                                 15                       16      750                      
  Mastectomy     2,880                               79.7                                 79                       84      2,959                    
                                                                                                                                                    
  Radiation Tx                                                                                                                                      0.405
  None           2,188                               63.8                                 53                       59.6    2,241                    
  Radiation Tx   1,239                               36.2                                 36                       40.4    1,275                    
                                                                                                                                                    
  Chemotherapy                                                                                                                                      0.898
  None           988                                 28                                   26                       27.4    1,014                    
  Chemotherapy   2,545                               72                                   69                       72.6    2,614                    
                                                                                                                                                    
  Hormone Tx                                                                                                                                        0.024
  None           1,553                               45.1                                 31                       33.3    1,584                    
  Hormone Tx     1,889                               54.9                                 62                       66.7    1,951                    

BCS = breast conserving surgery; Tx = therapy.

The ten-year RFS rate was 61.8% for the ILC and 69.5% for the IDC-NOS, respectively. The ten-year OS rate was 75% in ILC and 73.6% in IDC-NOS, respectively. There was no statistical significance in the RFS (relapse-free survival) and OS (overall survival) rates between the groups (Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}) even in stage-matched analysis (data not shown). In Table [3](#T3){ref-type="table"}, recurrence patterns and frequent sites of systemic recurrences are summarized. Both groups showed similar recurrence patterns. Lung and bone were the preferred sites of metastases in the IDC-NOS group (lung: 37.5%, bone: 36.5%). In the ILC group, bone was the most frequent site of metastasis followed by ovary (bone: 72.7%, ovary: 18.2%).

###### 

Recurrence patterns and distant sites of the first recurrence by histopathologic type

                                                   Histopathology                                                                                                                     
  ------------------------------------------------ ----------------------------------- ------------------------------------ ------------------------ ------- ------------------------ --------------
                                                   **Infiltrating ductal carcinoma**   **Infiltrating lobular carcinoma**   **Total**                                                 
                                                                                                                                                                                      
                                                   **Number of patients**              **%**                                **Number of patients**   **%**   **Number of patients**   ***P*value**
                                                                                                                                                                                      
  Pattern of recurrence                                                                                                                                                               0.097
  Locoregional recurrence                          123                                 14.4                                 3                        18.8    123                      
  Systemic recurrence                              480                                 56.1                                 12                       75.0    492                      
  Locoreginal recurrence and systemic recurrence   252                                 29.5                                 1                        6.3     253                      
                                                                                                                                                                                      
  Site of systemic recurrence                                                                                                                                                         
  Lung                                             264                                 37.5                                 1                        9.1     254                      
  Brain                                            50                                  7.1                                  0                        0       49                       
  Liver                                            105                                 14.9                                 0                        0       105                      
  Bone                                             257                                 36.5                                 8                        72.7    261                      
  Ovary                                            1                                   0.1                                  2                        18.2    2                        
  Pericardium, pleura                              10                                  1.4                                  0                        0       8                        
  Contalateral SCN                                 4                                   0.6                                  0                        0       7                        
  Other^a^                                         13                                  1.8                                  0                        0       19                       

Other^a^contains opposite breast (2), contralateral axilla (1), mediastinum (1), carcinomatosis (4), adrenal gland (2), multiple lymph node (1), neck node (2). SCN = supraclavicular lymph node.
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Discussion
==========

ILC is the second most common type of invasive breast cancers. According to the database of the National Cancer Institute from the period of 1992 up to 2001, 70% of all breast cancers were IDC, 8% were ILC, 7% were ductal/lobular type and the remaining 9% were various rare entities \[[@B1]\]. In American and European studies, the portion of ILC was reported to be about 10\~14% \[[@B7]\]. However, the portion of ILC in Korea was lower than that of outside the country, and it was reported to be 2\~4% \[[@B2],[@B8]\]. In this analysis, ILC accounted for 2.3%, a level similar to those found in other Korean studies. Taken together, the incidence of ILC in Korea is quite lower than that of Western countries.

Comparing to patients with IDCs, patients with ILC are older than those with IDC \[[@B7],[@B9]\]. However, there was no difference in the age at diagnosis between the two groups in our analysis. Low incidence of ILC and no difference in the age at diagnosis could be partly explained by different genetic or environmental factors of Korean breast cancer patients compared to those of Western countries \[[@B10]\] and the epidemiologic characteristics of Korean breast cancers \[[@B2]\]. The incidence of breast cancer in European and American women increases as they get older. In Korean women, however, the incidence of age distribution reaches the peak in their 40\'s, and then it declines afterwards. The most prevalent age for breast cancer in Korea is 10 years younger than that in Western countries \[[@B8]\].

Some studies reported that tumor size was slightly larger in the ILC group \[[@B9]\]. The lack of desmoplastic reaction may make the lesion impalpable and invisible, both clinically and mammographically, which could partly explain why lobular carcinomas were larger at diagnosis than IDCs \[[@B11]\]. However, no difference in tumor size was observed between the two groups in this study. Because of the high incidence of young breast cancer patients, the use of ultrasonography is very popular, which might in some part contribute to early detection of ILC as well as IDC in Korea.

Axillary lymph node involvement was not different between the two groups in our study. MacGrogan *et al*. \[[@B12]\] reported that the uniform appearance of bland tumor cells that lack cellular atypia and often have a low mitotic rate make it more difficult to correctly detect lobular cancer cells in metastatic lymph nodes. That is why nodal metastases are more often undetected in patients with ILC, and false-negative results are more frequently reported compared with ductal carcinomas \[[@B12]\]. Therefore, pathologists should be informed of the ILC case before interpreting the frozen slides of sentinel lymph nodes during surgery.

In agreement with other previous studies \[[@B13],[@B14]\], higher rate of ER expression and lower incidence of HER2 expression were demonstrated in this study. ILC is more often found to be multifocal, multicenteric and bilateral than IDCs. Bilateral involvement has been reported to be 20\~29% in lobular carcinoma \[[@B15],[@B16]\]. We also observed that bilateral involvement was more common in ILC (6.3%) compared to that in IDC-NOS (3.5%) (*P*= 0.013).

Several studies reported that ILC was less often treated with breast conserving surgery than IDC \[[@B7],[@B9]\]. This is attributed to the difficulty in defining tumor margins clinically or radiologically and related to higher probability of obtaining positive surgical margins due to tumor characteristics of multifocality or multicentricity \[[@B3]\]. Histologically ILC presents a loosely dispersed single cell pattern of growth throughout the stroma, lacks of desmoplastic reactions, and is often associated with lobular carcinoma in-situ and inflammatory cells around ducts may mimic the targetoid pattern of ILC \[[@B5],[@B17]\]. These can present notable diagnostic problems, especially in frozen section or in core needle biopsy specimens. In our study, less ILC patients underwent breast conserving surgery than IDC-NOS patients did, but there was no statistical difference. Some researchers reported that breast conserving surgery in ILC patients is not associated with increased local relapse rates at 5 years when compared with mastectomy. Therefore, ILC can be treated with breast conserving surgery when clear margin can be achieved \[[@B7],[@B18]\]. In terms of adjuvant therapy, both radiation therapy and chemotherapy were performed irrespective of histologic type. However, patients with ILC were more likely to undergo anti-estrogen therapy.

In terms of prognosis, some studies reported that the prognosis of ILC patients was similar to that of patients with IDC, and histologic type was not a factor affecting the prognosis \[[@B7],[@B11]\]. Others reported that early prognosis for ILC was better than that for IDC, while late prognosis for ILC was worse \[[@B3]\]. In this analysis, RFS and OS were similar between the two groups.

The locoregional or systemic recurrence pattern of ILC was similar to that of IDC-NOS in our study. Still, the distant metastatic sites of ILC differed from those of IDC-NOS. It was observed that ILC is less likely to affect the lungs, pleura, and CNS than IDC-NOS does. By contrast, bone, peritoneum, ovary, meniges, and the gastrointestinal system were much more likely to be affected by ILC \[[@B3],[@B19],[@B20]\]. As in other reports, the current study demonstrated that bone and ovary were the preferred sites of metastasis but lung and liver were rarely affected by ILC. Difference in favoring metastatic sites by histologic types might be attributable to the microenvironments of the ovary or peritoneum which might provide growth and survival factors that favor ILC cells over IDC cells \[[@B21],[@B22]\]. Some reported that loss of expression of the cell-cell adhesion molecule E-cadherin in ILC may decrease adhesiveness of cells and facilitate this type of infiltration \[[@B23]\]. Alternatively, cell size or shape with physical properties might favor certain microanatomical areas and that is more conductive to stopping or trapping these types of cells \[[@B19]\].

The limitation of our study was the HER-2 results. We defined HER-2 overexpression as 2+ or 3+ cases by HER-2 immunohistochemical testing in our study. During the periods under study approximately half of the study cohorts did not perform HER-2 immunohistochemical testing and furthermore, FISH was not a routine test for patients with 2+ results in our institution. This definition would overestimate the cases with HER-2 overexpression. However, this study is not confirmative but exploratory by retrospective review of data. Therefore, we concentrated on the sensitivity of HER-2 immunohistochemical testing. HER-2 immunohistochemical testing compared with FISH showed high sensitivity, negative predictive value, and overall accuracy when HER-2 overexpression was defined as 2+ or 3+ immunohistochemical results \[[@B24],[@B25]\]. Overall HER-2 overexpression rates of our study cohorts were 28.9% (576/1995), which did not significantly different from previous report \[[@B26]\].

In summary, low incidence of ILC in the Korean breast cancer population might be associated with younger age onset epidemiologic characteristics of the Korean population. ILC has some different characteristics from IDC such as more frequent estrogen receptor expression, less frequent HER-2 expression, high incidence of bilaterality and bone and ovary preference of metastases. Based on the histologic and biologic characteristics, researchers should be focused on the occurrence of contralateral breast cancers and preferred sites of metastasis during follow up. In Korea, the incidence of ILC is relatively lower than that in Western. However, increase in life expectancy or patients with breast carcinoma and change to westernized life style in Korea might lead to increase the incidence of ILC. Therefore, it should be necessary to understand clinicopathological features or tumor biology of ILC and to provide appropriate diagnostic or therapeutic guidelines for ILC.
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